Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The prognostic value of κ-free light chain (κ-FLC) index over the long term is unknown.
Objectives: The objective of the study was to determine whether κ-FLC index determined at disease onset predicts relapse activity and disability accrual during long-term follow-up.
Methods: Patients with a first demyelinating event of the central nervous system who had cerebrospinal fluid and serum sampling were eligible for inclusion. At baseline, demographics, clinical data, number of T2 hyperintense (T2L) and contrast-enhancing lesions (CEL) on MRI were assessed. During follow-up occurrence of relapses, Expanded Disability Status Scale (EDSS) scores and disease-modifying treatments (DMT) were registered. κ-FLC was measured by nephelometry and κ-FLC index calculated as (CSF κ-FLC/serum κ-FLC)/albumin quotient.
Results: Sixty-four patients with a median age at onset of 32 years (25th-75th percentile: 27-39) and a female predominance of 75% were followed over a median of 113 (90-129) months. Forty-six (72%) patients experienced relapse, 30 (47%) showed disability accrual. Multivariable Cox regression analysis adjusted for age, sex, disease duration, T2L, CEL and DMT revealed that κ-FLC index independently predicts time to relapse (per increase of 10: hazard ratio (HR) = 1.04, lower limit (LL)-confidence interval (CI) = 1.001, = 0.044) and disability accrual (per increase of 10: HR = 1.05, LL-CI = 1.009, = 0.022).
Conclusions: κ-FLC index predicts long-term disease activity independently of other risk factors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/13524585251344807 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relationship between brain atrophy and disability in a multi-site multiple sclerosis registry.
BMJ Neurol Open
July 2025
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
Background: In a retrospective multicentre cohort study, we explored the association between brain atrophy and multiple sclerosis (MS) disability using different MRI scanners and protocols at multiple sites.
Methods: Relapse-onset MS patients were included if they had two clinical MRIs 12 months apart and ≥2 Expanded Disability Status Scale (EDSS) scores. Percentage brain volume change (PBVC), percentage grey matter change (PGMC), fluid-attenuated inversion recovery (FLAIR) lesion volume change, whole brain volume (BV), grey matter volume (GMV), FLAIR lesion volume and T1 hypointense lesion volume were assessed by icobrain.
Evaluating recruitment, retention, and adherence patterns in the GET FIT fall prevention exercise trial in older, postmenopausal cancer survivors.
Support Care Cancer
July 2025
Division of Oncological Sciences, Oregon Health & Science University, 3455 SW US Veteran's Hospital Rd, Portland, OR, 97239, USA.
Purpose: The GET FIT trial tested fall prevention exercise approaches in older (50-75 years) post-chemotherapy, postmenopausal cancer survivors. We describe recruitment, retention, and adherence patterns from GET FIT to inform future trials.
Methods: Participants were recruited through multiple strategies (e.
Multiple sclerosis (MS) presents a spectrum of disease activities, making prognostication and treatment challenging. Our focus on aggressive MS (AMS), a subset lacking a universally accepted definition, aims to clarify its identification and management. Here we critically dissect the different criteria for defining AMS based on the latest research and consensus, the early prognostic factors which can unambiguously identify aggressive variants early in the disease course and the available high-efficacy therapies, with a special focus on autologous haematopoietic stem cell transplantation (AHSCT), which is considered a standard of care for relapsing-remitting MS refractory to disease-modifying treatments.
View Article and Find Full Text PDFEarly Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple Sclerosis.
Ann Clin Transl Neurol
July 2025
Department of Translational Biomedicines and Neurosciences (DiBraiN), University of Bari "Aldo Moro", Bari, Italy.
Objective: To evaluate the long-term impact of early intensive treatment (EIT) versus escalation (ESC) strategies using high-efficacy disease-modifying therapies (HE-DMTs) on disability progression in relapsing multiple sclerosis (RMS).
Methods: This observational study included 4878 RMS patients from the Italian Multiple Sclerosis Register. Eligible participants initiated their first disease-modifying therapy (DMT) within 3 years of disease onset and had ≥ 5 years of follow-up with at least three Expanded Disability Status Scale (EDSS) evaluations.
West Nile Virus Neuroinvasive Disease in Patients Treated With Anti-CD20 Therapies.
Neurol Clin Pract
August 2025
Department of Neurology, University of Colorado School of Medicine, Aurora, CO.
Background And Objectives: The literature on severe West Nile virus (WNV) neuroinvasive disease (WNND) in patients treated with anti-CD20 therapies is limited. We systematically characterize cases of WNND in the tertiary academic UCHealth system.
Methods: A retrospective cohort (January 2016 to January 2024) of patients with a validated diagnosis of WNND and anti-CD20 medication use was identified with electronic medical record query followed by individual chart review.